Connect Biopharma Holdings (CNTB)
(Delayed Data from NSDQ)
$2.00 USD
-0.02 (-0.99%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $2.00 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth B Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
CNTB 2.00 -0.02(-0.99%)
Will CNTB be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CNTB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CNTB
What Makes Connect Biopharma Holdings Limited Sponsored ADR (CNTB) a Strong Momentum Stock: Buy Now?
CNTB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for CNTB
Connect Biopharma (CNTB) Expands Board with New Director Appointment | CNTB Stock News
Connect Biopharma (CNTB) Gains Attention with Promising Treatment | CNTB Stock News
Connect Biopharma Appoints Industry Veteran Jim Schoeneck to its Board of Directors | CNTB ...
Northland Begins Coverage on Connect Biopharma (CNTB) with Positive Outlook | CNTB Stock News
Connect Biopharma announces expansion of board, appoints Schoeneck as director